A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Amgen
Pfizer
M.D. Anderson Cancer Center
University of Maryland, Baltimore
Eli Lilly and Company
H. Lee Moffitt Cancer Center and Research Institute
University Health Network, Toronto
Ohio State University Comprehensive Cancer Center
Blueprint Medicines Corporation
Canadian Cancer Trials Group
Cantargia AB
Blueprint Medicines Corporation
Fox Chase Cancer Center
BioNTech SE
Celgene
Abramson Cancer Center at Penn Medicine
Alliance for Clinical Trials in Oncology
University of California, Davis
AbbVie
M.D. Anderson Cancer Center
Radiation Therapy Oncology Group
M.D. Anderson Cancer Center
Cancer Research and Biostatistics Clinical Trials Consortium
Memorial Sloan Kettering Cancer Center
GlaxoSmithKline
National Cancer Institute (NCI)